FXR2

Across TCGA pan-cancer cohorts, FXR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FXR2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FXR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FXR2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where FXR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.937	0.672	<.001	26	view →
LUAD	DFS	Median	All	0.877	0.950	.009	19	view →
CCRCC	DFS	Tertile	IV	0.961	0.196	.024	8	view →
COAD	DFS	Median	III,IV	1.000	0.838	.036	6	view →
HNSC	OS	Median	All	0.613	0.816	.003	6	view →
PDAC	OS	Tertile	IV	0.490	0.973	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FXR2–LSCC (DFS)

Open the LSCC breakdown →